FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

DARGAN CHARLES K
2. Issuer Name and Ticker or Trading Symbol

BIOLARGO, INC. [ BLGO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

18851 NE 29TH AVENUE, SUITE 700
3. Date of Earliest Transaction (MM/DD/YYYY)

1/31/2020
(Street)

AVENTURA, FL 3318
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase Common Stock $0.50 1/31/2020  J (1)  V   10000  1/31/2010 1/31/2020 Common stock 10000 $0 (2)3089000 D  
Option to Purchase Common Stock $0.575 2/1/2020  J (1)  V   60000  2/1/2010 2/1/2020 Common stock 60000 $0 (2)3029000 D  
Option to Purchase Common Stock $0.21 2/25/2020  A   27500    2/25/2020 2/25/2030 Common stock 27500 $0 (3)3056500 D  
Option to Purchase Common Stock $0.21 2/25/2020  A   400000 (4)   2/25/2020 2/25/2030 Common stock 400000 $0 (5)3456500 D  

Explanation of Responses:
(1) This transaction reports the expiration, without exercise, of an Option to purchase common stock issued by Issuer to Reporting Person.
(2) This Option was originally issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer during the time period specific in the Engagement Agreement between the Reporting Person and the Issuer in effect on the date the Option was issued.
(3) This Option was issued to Reporting Person to replace options to purchase 110,000 shares that had been issued as sole compensation to the provision of services to the Issuer and had expired, unexercised.
(4) The Option is exercisable according to its vesting schedule: (i) 75,000 shares as of December 31, 2019, and then (ii) in equal monthly installments of 25,000 shares beginning January 31, 2020, so long as the Engagement Extension Agreement dated February 25, 2020, between Reporting Owner and Issuer, remains in force and effect.
(5) This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from October 1, 2019 through January 31, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
DARGAN CHARLES K
18851 NE 29TH AVENUE
SUITE 700
AVENTURA, FL 3318


Chief Financial Officer

Signatures
/s/ John R. Browning, Attorney-in-fact2/27/2020
**Signature of Reporting PersonDate

BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more BioLargo (QB) Charts.
BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more BioLargo (QB) Charts.